Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
MAINZ, Germany, March 07, 2017 -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it will present interim data from an ongoing Phase I/II clinical trial of its Lipo-MERIT vaccine in patients with malignant melanoma at the 2017 Annual Meeting of the American Association for Cancer Research (AACR), taking place April 1 – 5 in Washington, DC. This is the first example of a clinically applied systemic mRNA-based cancer immunotherapy.
| Permanent Abstract Number: CT034 | |||
| Poster: | “A First-in-Human Phase I/II Clinical Trial Assessing Novel mRNA-lipoplex Nanoparticles for | ||
| Potent Melanoma Immunotherapy” | |||
| Date: | Monday, April 3, 2017 | ||
| Session: | PO.CT01 - Phase I Clinical Trials in Progress | ||
| Time: | 8:00AM – 12:00PM Eastern Daylight Time | ||
| Location: | Poster Section 33 | ||
The Phase I/II dose escalation Lipo-MERIT trial (NCT02410733) in melanoma patients assesses the safety and tolerability as well as the potency of inducing antigen-specific immune responses of the first systemic mRNA vaccine to be developed based on BioNTech’s mRNA nanoparticle immunotherapy platform.
About BioNTech AG
BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The company combines all building blocks of individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech’s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.
More information about BioNTech is available at www.biontech.de.
For meeting requests or further information, please contact: General Inquiries: BioNTech AG Regina Jehle Tel: +49 6131 9084 1273 Email: [email protected] US Media & Investors: ICR Healthcare James Heins / Stephanie Carrington Tel: +1 203 682 8251 Tel: +1 646 277 1282 Email: [email protected] Email: [email protected] International Media & Investor Inquiries: akampion Dr. Ludger Wess / Ines-Regina Buth Tel: +49 40 8816 5964 Tel: +49 30 2363 2768 Email: [email protected]
